HuGE Literature Finder
Records
1
-
21
| Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Annals of hematology 2018 Jan 97 (1): 109-121. Boddu Prajwal, Masarova Lucia, Verstovsek Srdan, Strati Paolo, Kantarjian Hagop, Cortes Jorge, Estrov Zeev, Pierce Sherry, Pemmaraju Nave |
| Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood advances 2017 Sep 1 (20): 1729-1738. Spiegel Jay Y, McNamara Caroline, Kennedy James A, Panzarella Tony, Arruda Andrea, Stockley Tracy, Sukhai Mahadeo, Thomas Mariam, Bartoszko Justyna, Ho Jenny, Siddiq Nancy, Maze Dawn, Schimmer Aaron, Schuh Andre, Sibai Hassan, Yee Karen, Claudio Jamie, Devlin Rebecca, Minden Mark D, Kamel-Reid Suzanne, Gupta Vik |
| Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leukemia research 2017 Jun 60 18-23. Barosi Giovanni, Massa Margherita, Campanelli Rita, Fois Gabriela, Catarsi Paolo, Viarengo Gianluca, Villani Laura, Poletto Valentina, Bosoni Tiziana, Magrini Umberto, Gale Robert P, Rosti Vittor |
| Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. American journal of hematology 2016 Feb . Patnaik Mrinal M, Lasho Terra L, Finke Christy M, Hanson Curtis A, King Rebecca L, Ketterling Rhett P, Gangat Naseema, Tefferi Ayal |
| Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. American journal of hematology 2015 Sep . Bai Jie, Ai Limei, Zhang Lei, Yang Fengchun, Zhou Yuan, Xue Yanpi |
| Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms. Acta haematologica 2015 133 (2): 193-8. Wojtaszewska Marzena, Iwo?a Ma?gorzata, Lewandowski Krzyszt |
| CALR mutation screening in pediatric primary myelofibrosis. Pediatric blood & cancer 2014 Dec 61 (12): 2256-62. An Wenbin, Wan Yang, Guo Ye, Chen Xiaojuan, Ren Yuanyuan, Zhang Jingliao, Chang Lixian, Wei Wei, Zhang Peihong, Zhu Xiaof |
| Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014 Aug 124 (7): 1062-9. Rumi Elisa, Pietra Daniela, Pascutto Cristiana, Guglielmelli Paola, Martínez-Trillos Alejandra, Casetti Ilaria, Colomer Dolors, Pieri Lisa, Pratcorona Marta, Rotunno Giada, Sant'Antonio Emanuela, Bellini Marta, Cavalloni Chiara, Mannarelli Carmela, Milanesi Chiara, Boveri Emanuela, Ferretti Virginia, Astori Cesare, Rosti Vittorio, Cervantes Francisco, Barosi Giovanni, Vannucchi Alessandro M, Cazzola Mario, |
| Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 2014 Apr 123 (14): 2157-60. Guglielmelli Paola, Biamonte Flavia, Rotunno Giada, Artusi Valentina, Artuso Lucia, Bernardis Isabella, Tenedini Elena, Pieri Lisa, Paoli Chiara, Mannarelli Carmela, Fjerza Rajmonda, Rumi Elisa, Stalbovskaya Viktoriya, Squires Matthew, Cazzola Mario, Manfredini Rossella, Harrison Claire, Tagliafico Enrico, Vannucchi Alessandro M, , |
| Prognostic score including gene mutations in chronic myelomonocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Jul 31 (19): 2428-36. Itzykson Raphaël, Kosmider Olivier, Renneville Aline, Gelsi-Boyer Véronique, Meggendorfer Manja, Morabito Margot, Berthon Céline, Adès Lionel, Fenaux Pierre, Beyne-Rauzy Odile, Vey Norbert, Braun Thorsten, Haferlach Torsten, Dreyfus François, Cross Nicholas C P, Preudhomme Claude, Bernard Olivier A, Fontenay Michaela, Vainchenker William, Schnittger Susanne, Birnbaum Daniel, Droin Nathalie, Solary Er |
| Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases. Haematologica 2012 Dec 97 (12): 1890-4. Schnittger Susanne, Bacher Ulrike, Alpermann Tamara, Reiter Andreas, Ulke Madlen, Dicker Frank, Eder Christiane, Kohlmann Alexander, Grossmann Vera, Kowarsch Andreas, Kern Wolfgang, Haferlach Claudia, Haferlach Torst |
| Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica 2011 Oct 96 (10): 1462-9. Stein Brady L, Williams Donna M, O'Keefe Christine, Rogers Ophelia, Ingersoll Roxann G, Spivak Jerry L, Verma Amit, Maciejewski Jarek P, McDevitt Michael A, Moliterno Alison |
| Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Clinical lymphoma, myeloma & leukemia 2011 Jun 11 Suppl 1 S25-7. Passamonti Frances |
| Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. Clinics (São Paulo, Brazil) 2011 66 (5): 793-9. Machado-Neto João Agostinho, Traina Fabiola, Lazarini Mariana, Campos Paula de Melo, Pagnano Katia Borgia Barbosa, Lorand-Metze Irene, Costa Fernando Ferreira, Saad Sara T Olal |
| JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia. The Korean journal of hematology 2010 Mar 45 (1): 46-50. Jekarl Dong Wook, Han Sang Bong, Kim Myungshin, Lim Jihyang, Oh Eun-Jee, Kim Yonggoo, Kim Hee-Je, Min Woo-Sung, Han Kyung |
| Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations. Cancer genetics and cytogenetics 2010 Feb 197 (1): 1-7. Millecker Laura, Lennon Patrick A, Verstovsek Srdan, Barkoh Bedia, Galbincea John, Hu Peter, Chen Su S, Jones D |
| Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC cancer 2010 10 (1): 401. Rocquain Julien, Carbuccia Nadine, Trouplin Virginie, Raynaud Stéphane, Murati Anne, Nezri Meyer, Tadrist Zoulika, Olschwang Sylviane, Vey Norbert, Birnbaum Daniel, Gelsi-Boyer Véronique, Mozziconacci Marie-Joel |
| Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009 Aug 114 (8): 1477-83. Guglielmelli Paola, Barosi Giovanni, Specchia Giorgina, Rambaldi Alessandro, Lo Coco Francesco, Antonioli Elisabetta, Pieri Lisa, Pancrazzi Alessandro, Ponziani Vanessa, Delaini Federica, Longo Giovanni, Ammatuna Emanuele, Liso Vincenzo, Bosi Alberto, Barbui Tiziano, Vannucchi Alessandro |
| HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009 Mar 18 (3): 929-34. Andrikovics Hajnalka, Meggyesi Nora, Szilvasi Aniko, Tamaska Julia, Halm Gabriella, Lueff Sandor, Nahajevszky Sarolta, Egyed Miklos, Varkonyi Judit, Mikala Gabor, Sipos Andrea, Kalasz Laszlo, Masszi Tamas, Tordai Atti |
| JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008 Jan 93 (1): 34-40. Schmitt-Graeff Annette H, Teo Soon-Siong, Olschewski Manfred, Schaub Franz, Haxelmans Sabine, Kirn Andreas, Reinecke Petra, Germing Ulrich, Skoda Radek |
| Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders. Genetic testing and molecular biomarkers 0 15 (1-2): 17-21. Ayad Mona Wagdy, Nafea Dal |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jan 20, 2022
- Content source: